Gamida Cell Ltd. (NASDAQ:GMDA) Q3 2023 Earnings Call Transcript

Page 2 of 2

Abbey Jenkins: Thank you, Chris. Thank you all for joining us today. To recap, we remain confident in our team’s ability to deliver Omisirge to an increasing volume of patients in need of a stem cell transplant in transplant centers across the US. We believe in Omisirge’s ability to achieve its market potential and increase patient access to Allogeneic Stem Cell transplant. Thank you, everyone for joining us on today’s call, and we look forward to providing further updates on future calls. Thank you.

Operator: Thank you very much. Ladies and gentlemen, that concludes today’s event, and you may now disconnect your lines.

Follow Gamida Cell Ltd. (NASDAQ:GMDA)

Page 2 of 2